Bursa rides US–China tariff truce, FBM KLCI ends higher at 1,567.90
At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 4.66 points, or 0.30 per cent, to close at 1,567.90 from yesterday's close of 1,563.24.
The benchmark index opened 1.41 points lower at 1,561.83, marking its day's low, and subsequently hit a high of 1,572.97 in early trade.
The broader market was positive, with advancers leading decliners 513 to 477, while 507 counters were unchanged, 1,024 untraded and eight suspended.
Turnover edged down to 2.53 billion units worth RM2.15 billion from 2.54 billion units worth RM2.20 billion yesterday.
Rakuten Trade Sdn Bhd vice-president of equity research Thong Pak Leng said major Asian indices also trended positively as investors welcomed news that the US and China had agreed on Monday to extend their tariff truce by 90 days, avoiding steep duties that could have disrupted trade flows.
'The deal maintains existing US tariffs at 30 per cent and Chinese tariffs at 10 per cent, providing additional time for negotiations and lifting investor sentiment across the region,' he told Bernama.
Meanwhile, he said market sentiment was further boosted by optimism over easing geopolitical tensions, as US President Donald Trump and Russian President Vladimir Putin are set to meet in Alaska on Friday to discuss the war in Ukraine.
Back home, Thong said the benchmark index closed at 1,567.90, edging above the key 1,565 resistance, and a clear breakout above this threshold will set the stage for further gains.
'As such, our weekly FBM KLCI target remains at the 1,550-1,580 range,' he added.
Traders are also awaiting key US inflation data, which could signal the Federal Reserve's next policy move.
The US consumer price index (CPI) report, due for release tonight, is expected to show an increase, with consensus estimates placing headline CPI at 2.8 per cent and core CPI at 3.0 per cent for July — up from 2.7 per cent and 2.9 per cent, respectively, in June.
Among the heavyweights, Maybank added 6.0 sen to RM9.71, CIMB perked up 7.0 sen to RM7.01, while Tenaga Nasional eased 8.0 sen to RM13.58, IHH Healthcare slipped 14 sen to RM6.82, and Public Bank was flat at RM4.40.
Of the most active counters, Classita rose half-a-sen to 9.5 sen, NexG gained 2.5 sen to 40 sen, while Zetrix AI decreased 1.5 sen to 88 sen, Tanco trimmed by 2.0 sen to 72.5 sen, and TWL was flat at 2.5 sen.
Across the broader market, the FBM Emas Index increased 28.37 points to 11,675.50, the FBMT 100 Index advanced 26.46 points to 11,456.18, the FBM Emas Shariah Index edged up 17.71 points to 11,665.38, the FBM ACE Index climbed 17.92 points to 4,638.14, and the FBM 70 Index rose 5.0 points to 16,600.64.
By sector, the Financial Services Index increased 86.82 points to 17,814.65, the Industrial Products and Services Index added 1.28 points to 160.06, the Plantation Index surged 67.73 points to 7,531.81, and the Energy Index put on 3.02 points to 738.38.
The Main Market volume improved to 1.56 billion units valued at RM1.95 billion from Monday's 1.52 billion units valued at RM2.01 billion.
Warrants turnover declined to 707.18 million units worth RM92.44 million from 732.96 million units worth RM90.85 million previously.
The ACE Market volume decreased to 251.24 million units worth RM106.41 million from 279.82 million units worth RM90.63 million yesterday.
Consumer products and services counters accounted for 432.48 million shares traded on the Main Market; industrial products and services (187.12 million), construction (88.88 million), technology (270.13 million), financial services (78.73 million), property (206.67 million), plantation (14.81 million), REITs (21.93 million), closed-end fund (5,500), energy (96.50 million), healthcare (81.98 million), telecommunications and media (25.96 million), transportation and logistics (21.36 million), utilities (36.66 million), and business trusts (184,600). — Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
24 minutes ago
- Malaysian Reserve
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ — USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR). Global Market Insights estimates the global oncology market at US$345.1 billion in 2025 and forecasts it will climb to US$866.1 billion by 2034, growing at a robust 10.8% CAGR. The U.S. alone is expected to contribute $377.1 billion to that total. Vision Research Reports projects an even larger figure for the global cancer drug sector, predicting it will surpass US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. 'We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year,' said Jared Kelly, CEO of Oncolytics. 'As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors.' The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically 'cold' tumors—those typically invisible to the immune system—into 'hot' tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. 'This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action,' said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. 'We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep.' Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. CONTINUED… Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported strong Q2 2025 results with $60 million in total product revenue, driven primarily by its breakthrough melanoma therapy Amtagvi, which treated over 100 patients in the second quarter. 'Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing ATC growth continues and large community practices begin treating patients,' said Frederick Vogt, Ph.D., J.D., Interim President and CEO of Iovance. 'We expect our first ex-U.S. regulatory approval imminently and remain on track to provide updates on our clinical programs.' The company's tumor-infiltrating lymphocyte (TIL) therapy—which uses a patient's own immune cells to fight cancer—generated $54.1 million in revenue and represents the first FDA-approved T-cell therapy for solid tumors, offering new hope for advanced melanoma patients who have tried other treatments without success. With expanded clinical trials planned for lung cancer and endometrial cancer, plus international approvals expected in Canada and other markets, Iovance is positioned to bring its innovative cancer treatment to patients worldwide. Fate Therapeutics, Inc. (NASDAQ: FATE) recently announced promising clinical progress for its off-the-shelf CAR T-cell therapy FT819, which showed lasting responses in lupus patients and received FDA clearance to begin trials for a solid tumor program targeting MICA/B proteins. While primarily focused on autoimmune diseases, the company's next-generation FT836 CAR T-cell therapy represents a significant advancement in cancer treatment as it's designed to target solid tumors without requiring harsh conditioning chemotherapy, potentially making the treatment safer and more accessible. 'Building on this momentum, we are also working closely with the FDA under our RMAT designation with the goal of commencing our registrational study for FT819 in SLE and LN in 2026,' said Bob Valamehr, Ph.D., MBA, President and CEO of Fate Therapeutics. 'Additionally, we continue to strengthen our broader pipeline programs with an extended partnership with Ono Pharmaceuticals, and advancements in bringing our next-generation, off-the-shelf CAR T cells with Sword and Shield™ technology toward the clinic.' The company's stem cell-based platform continues to advance multiple programs, including partnerships for HER2-positive solid tumors, positioning Fate as a leader in developing ready-made cancer cell therapies. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) remains on track to submit its application for INO-3107 in the second half of 2025, targeting Recurrent Respiratory Papillomatosis (RRP), a rare cancer-related condition caused by HPV that affects the airways. The company's DNA medicine platform represents a novel approach to treating HPV-related diseases and cancers, with INO-3107 showing significant clinical benefit by reducing the need for repeated surgeries in RRP patients from an average of 4.1 procedures annually to just 0.9 procedures. 'We believe that INO-3107 could become the preferred treatment option for Recurrent Respiratory Papillomatosis (RRP) patients and their physicians—a treatment option with the potential to change the trajectory of this disease,' said Dr. Jacqueline Shea, President and CEO of INOVIO. 'I look forward to building on the significant progress of this past quarter and providing updates as we work toward a potential approval date in mid-2026.' Beyond RRP, Inovio's technology platform is designed to treat various HPV-related cancers and other tumors by teaching the body's immune system to recognize and fight cancer cells. With breakthrough therapy designation from the FDA and plans for a trial involving 100 patients, INO-3107 could become the first DNA-based therapy approved for treating this serious cancer-related condition. Nektar Therapeutics (NASDAQ: NKTR) reported impressive Phase 2b data for rezpegaldesleukin in treating moderate to severe atopic dermatitis, with the company positioning this immune system regulator as a first-in-class treatment for autoimmune diseases. While primarily focused on autoimmune conditions, Nektar's pipeline includes NKTR-255, a treatment designed to boost the immune system's ability to fight cancer, which is being tested in multiple ongoing clinical trials with various partners. 'As a first-in-class, T regulatory cell biologic, rezpegaldesleukin is poised to become an important novel mechanism to treat millions of patients with autoimmune disorders,' said Howard W. Robin, President and CEO of Nektar. 'Finally, we are making significant progress on advancing preclinical studies with a new bispecific antibody, NKTR-0166, which combines the TNFR2 epitope with a validated antibody target.' The company's technology platform creates novel treatments that could potentially address both autoimmune diseases and cancer by enhancing the immune system's cancer-fighting abilities. With additional data expected from hair loss trials in December 2025 and continued development of next-generation programs, Nektar is advancing a unique approach to immune system therapy that could benefit millions of patients with serious diseases. Source: CONTACT: USA NEWS GROUP info@ (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ('MIQ'). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo –
Barnama
5 hours ago
- Barnama
World Bank Approves US$10 Mln Emergency Aid For Cape Verde
PRAIA, Cape Verde, Aug 14 (Bernama-Xinhua) -- The World Bank has approved US$10 million in emergency assistance to support Cape Verde's response to heavy rains that have left eight people dead and three others missing, Cape Verdean Prime Minister Ulisses Correia e Silva has said, Xinhua reported. In a post on his official social media page Wednesday, Correia e Silva said the aid was activated under a cooperation programme aimed at supporting the government's efforts toward a resilient and equitable economic recovery, with the World Bank authorising an immediate disbursement. He thanked the World Bank Group for its "swift response" to Cape Verde's request and its "strong sense of solidarity" in addressing urgent social and infrastructure needs to protect communities and rebuild with greater resilience.
The Star
5 hours ago
- The Star
India and China eye resumption of border trade
NEW DELHI: India and China are discussing resuming border trade five years after it was halted, foreign ministry officials on both sides have said, as US tariffs disrupt the global trade order. Past trade between the neighbours across the icy and high-altitude Himalayan border passes was usually small in volume, but any resumption is significant for its symbolism. The two major economic powers have long competed for strategic influence across South Asia. However, the two countries, caught in global trade and geopolitical turbulence triggered by US President Donald Trump's tariff regime, have moved to mend ties. Chinese Foreign Minister Wang Yi is expected for talks in New Delhi on Monday (Aug 11), according to Indian media, after his counterpart Subrahmanyam Jaishankar visited Beijing in July. That, as well as agreements to resume direct flights and issue tourist visas, has been seen as an effort to rebuild a relationship damaged after a deadly 2020 border clash between troops. "For a long time, China-India border trade cooperation has played an important role in improving the lives of people living along the border," China's foreign ministry said in a statement sent to AFP on Thursday. It said the two sides have "reached a consensus on cross-border exchanges and cooperation, including resumption of border trade". New Delhi's junior foreign minister, Kirti Vardhan Singh, told parliament last week that "India has engaged with the Chinese side to facilitate the resumption of border trade". No restart date was given by either side. - 'Transitions and challenges' - Successive US administrations have seen India as a longstanding ally with like-minded interests when it comes to China. India is part of the Quad security alliance with the United States, as well as Australia and Japan. However, ties between New Delhi and Washington have been strained by Trump's ultimatum for India to end its purchases of Russian oil, a key source of revenue for Moscow as it wages its military offensive in Ukraine. The United States will double new import tariffs on India from 25 percent to 50 percent by August 27 if New Delhi does not switch crude suppliers. Indian foreign ministry spokesman Randhir Jaiswal told reporters on Thursday that the partnership between New Delhi and Washington had "weathered several transitions and challenges". Jaiswal said India hoped that the "relationship will continue to move forward based on mutual respect and shared interests". He said India "stands ready" to support the efforts to end the Ukraine war and endorses the summit to be held between Trump and Russian President Vladimir Putin in Alaska on Friday. Prime Minister Narendra Modi, according to Indian media, might also visit China in late August. It would be Modi's first visit since 2018, although it has not been confirmed officially. Beijing has said that "China welcomes Prime Minister Modi" for the Shanghai Cooperation Organization summit opening on August 31. - AFP
